Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
BioHarvest Sciences ( (TSE:BHSC) ) has shared an update.
BioHarvest Sciences has announced the launch of its new Contract Development and Manufacturing Organization (CDMO) Services division, marking a transformative year in 2024. This division, anchored by a partnership with Tate & Lyle, positions BioHarvest to deliver life-changing molecules for major industries using its Botanical Synthesis technology. The company’s Nasdaq listing in the U.S. further supports its growth and visibility, indicating a significant step change in revenue growth and financial performance anticipated for 2025 and beyond.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a company pioneering in the field of Botanical Synthesis technology. It focuses on developing innovative solutions in pharmaceuticals, nutraceuticals, cosmetics, and nutrition/sweetener industries by creating unique molecules that can be produced consistently and economically at large scale.
YTD Price Performance: 0.0%
Average Trading Volume: 5,296
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$154.2M
See more data about BHSC stock on TipRanks’ Stock Analysis page.
